Pharma Sector

Glenmark Pharma:

What happened: Q1 FY26 profit fell ~86% YoY as per today’s updates—stock in focus. Why it matters: Earnings resets remind that pharma = US generics pricing, product mix, and R&D spends. How to read it: Track USFDA observations, ANDA launches, API supply, and debt. Beginner takeaway: Don’t buy just because “pharma is defensive.” Read the results deck before decisions.